Proposed Mechanism of Action
Herceptin (trastuzumab) is a monoclonal antibody specifically designed to target HER2.
It is believed to block downstream signaling pathways.
Herceptin flags the tumor cell for destruction by the body's immune system, known as antibody dependent cellular cytotoxicity (ADCC).
Herceptin prevents HER2 shedding.1
Herceptin may work to enhance the effects of chemotherapy as shown in multiple pre-clinical studies.1
- Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744-4749.
- American Cancer Society. Breast cancer facts & figures 2015-2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-046381.pdf. Accessed April 6, 2016.